Sequenom (SQNM) Announces Prelim. Q1 Test Volumes, Increases FY Volume Outlook

April 16, 2012 7:39 AM EDT
Get Alerts SQNM Hot Sheet
Trade SQNM Now!
Join SI Premium – FREE
Sequenom, Inc. (NASDAQ: SQNM) today reported that more than 12,700 total tests, including in excess of 4,900 MaterniT21 PLUS laboratory-developed tests (LDT) offered by Sequenom Center for Molecular Medicine (Sequenom CMM), were accessioned during the first quarter of 2012. This equates to an annualized run rate in excess of 30,000 MaterniT21 PLUS LDTs, based on the volume processed during the last week of the quarter.

Due to the successful growth in adoption year-to-date, the Company is increasing its internal goal to 40,000 MaterniT21 PLUS LDTs billed in 2012, up from the original goal of 25,000 tests billed for the year.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Guidance

Add Your Comment